Companies

Sandoz has struck a new deal with Samsung Bioepis covering up to five early-stage biosimilars, expanding an existing alliance as the Swiss-based firm ramps up investment, reorganizes its business and targets a wave of upcoming biologics loss-of-exclusivity opportunities.

Brazil’s EMS has agreed to acquire Sanofi’s Medley generics business in a deal aimed at strengthening its position in the country’s off-patent medicines market, with the combined platform potentially reaching about 32% share pending regulatory approval.

Previously known only as AMP-007, the generic Atrovent HFA inhaler is now set for a Q2 launch with six months of exclusivity.

Cipla will form a 60:40 joint venture with Kemwell Biopharma to develop, manufacture and commercialize biologics for global markets. The India-based venture will leverage Kemwell’s Bengaluru biologics facility and support development, licensing, and export of biologic products.

Viatris will cut up to 10% of its global workforce – around 3,000 jobs – as part of a three-year restructuring plan targeting $650m in gross savings, with $250m set for reinvestment to boost growth and innovation, yielding roughly $400m in net savings by 2029.

Sandoz enjoyed good sales and profit growth in 2025, with a significant increase in free cash flow allowing the firm to continue investing in its major European biosimilars manufacturing network.

With its primary endpoint achieved, the German biosimilar developer turns to finalizing global regulatory dossiers.

Organon’s management declined to discuss the ongoing review, leaving analysts questioning whether the latest issue could signal broader governance or oversight challenges.

With roughly five years until key exclusivities begin to expire, Generics Bulletin examines how the race to develop biosimilar versions of Dupixent is beginning to take shape.

Aside from logging generally solid earnings, South Korean pharma firms Yuhan, Hanmi and SK Biopharmaceuticals disclosed updated R&D strategies involving obesity treatments and new modalities.

The Korean player plans to expand its biosimilar portfolio to more than 40 products by 2038, while advancing late-stage candidates including a streamlined Phase III trial of its secukinumab biosimilar.

Phlow and Fresenius Kabi are partnering in the US to establish a fully domestic manufacturing pathway for epinephrine injection, with launch targeted for 2027 pending approvals. The collaboration is aimed at addressing the current lack of a US-based API producer.